← Back to Search

Other

Intervention (Urolithin A: Mitopure) Group for Chronic Obstructive Pulmonary Disease

Phase 2

Recruiting

Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 28

Awards & highlights

Study Summary

"This trial aims to test the effectiveness of a nutritional oral supplement in improving exercise performance in patients with Chronic Obstructive Pulmonary Disease (COPD) who are also participating in a Pulmonary Rehabilitation

Who is the study for?

This trial is for individuals with Chronic Obstructive Pulmonary Disease (COPD) who are already participating in a Pulmonary Rehabilitation program. The study aims to see if adding a nutritional supplement can improve muscle function and overall health.Check my eligibility

What is being tested?

The trial is testing the effects of Urolithin A, an oral supplement thought to enhance muscle energy production, against a placebo. It's part of a pilot study to determine if larger trials should be conducted on its benefits alongside standard COPD treatments.See study design

What are the potential side effects?

While specific side effects aren't listed here, previous studies suggest that Urolithin A has been safe and tolerable in adults. Any potential side effects will likely be monitored closely during the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 28

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 28

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Constant Work Rate Exercise Test (CRWET)

Secondary outcome measures

6-Minute Walk Test (6MWT)

Adverse events

Blood levels of the intervention

+12 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Intervention (Urolithin A: Mitopure) GroupActive Control1 Intervention

Participants will participate in a standard PR program and will receive the oral supplement.

Group II: Placebo GroupPlacebo Group1 Intervention

Participants will participate in a standard PR program and will receive placebo.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Amazentis SAIndustry Sponsor

16 Previous Clinical Trials

1,139 Total Patients Enrolled

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor

447 Previous Clinical Trials

159,742 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available openings for patients to participate in this study?

"Indeed, details on clinicaltrials.gov highlight that this study is actively seeking participants. The trial was initially listed on 3rd November 2024 and the latest update was made on 19th March 2024. This research endeavor aims to recruit a total of 10 individuals from one designated site."

Answered by AI

What is the upper limit for participant enrollment in this research investigation?

"Indeed, clinicaltrials.gov data indicates that this trial is actively enrolling participants. The trial was first listed on March 11th, 2024 and last updated on March 19th, 2024. The study aims to recruit ten patients from a single site."

Answered by AI

What are the safety considerations for patients involved in the Urolithin A intervention group?

"Power's team estimates the safety of the Intervention (Urolithin A) Group at a level 2 on the scale due to this being a Phase 2 trial. While there is data supporting its safety, efficacy evidence is currently lacking."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Oral Supplementation During PR Participation in COPD

Bryan Ross 2024. "Oral Supplementation During PR Participation in COPD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06324214.